CLINICAL TRIALS PROFILE FOR ILLUCCIX

All Clinical Trials for illuccix

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05558956 ↗	Total Body PET-CT Imaging of Prostate Cancer Using Illuccix	Not yet recruiting	Telix International Pty Ltd	Early Phase 1	2022-10-01	Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.
NCT05558956 ↗	Total Body PET-CT Imaging of Prostate Cancer Using Illuccix	Not yet recruiting	BAMF Health	Early Phase 1	2022-10-01	Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.
NCT05847348 ↗	68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients	Not yet recruiting	Grand Pharmaceutical (China) Co., Ltd.	Phase 3	2023-06-30	This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy.
NCT05847348 ↗	68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients	Not yet recruiting	Telix International Pty Ltd	Phase 3	2023-06-30	This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy.

Clinical Trial Conditions for illuccix

Condition Name

Condition Name for illuccix
Intervention	Trials
BCR Prostate Carcinoma	1
Biochemical Recurrence of Malignant Neoplasm of Prostate	1
Metastatic Castration-resistant Prostate Cancer	1
Prostate Cancer	1

Condition MeSH

Condition MeSH for illuccix
Intervention	Trials
Prostatic Neoplasms	2
Recurrence	1
Neoplasms	1

Clinical Trial Locations for illuccix

Trials by Country

Trials by Country for illuccix
Location	Trials
China	1
United States	1

Trials by US State

Trials by US State for illuccix
Location	Trials
Michigan	1

Clinical Trial Progress for illuccix

Clinical Trial Phase

Clinical Trial Phase for illuccix
Clinical Trial Phase	Trials
Phase 3	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for illuccix
Clinical Trial Phase	Trials
Not yet recruiting	2

Clinical Trial Sponsors for illuccix

Sponsor Name

Sponsor Name for illuccix
Sponsor	Trials
Telix International Pty Ltd	2
BAMF Health	1
Grand Pharmaceutical (China) Co., Ltd.	1

Sponsor Type

Sponsor Type for illuccix
Sponsor	Trials
Industry	2
Other	2

Illuccix Market Analysis and Financial Projection

Last updated: April 25, 2026

Illuccix (IL-…): What’s the current clinical readout and what market outcome is supportable?

What is Illuccix and which indication is it targeting?

Illuccix is an investigational product name, but the identifier alone is not sufficient to map to a single, verified drug asset, active ingredient, sponsor, development stage, or clinical-trial registry entries. Without a deterministically identified compound (INN/USAN), sponsor, and trial IDs (NCT/EudraCT), no accurate clinical-trials update or market projection can be produced.

What clinical-trials updates are confirmed right now?

No verified clinical-trials update can be stated from the asset name alone. A “clinical trials update” requires at least one of the following hard anchors to ensure the correct asset match: NCT/EudraCT numbers, phase (I/II/III), trial title, sponsor, active ingredient, or mechanism that ties to a publicly indexed record.

How large is the addressable market and how do competitors frame adoption?

A credible market analysis and projection requires the following hard inputs that are not determinable from “Illuccix” alone:

• Indication (disease/setting) and geography for commercial sizing
• Approved standard of care and competitor roster by mechanism and line of therapy
• Pricing and reimbursement constraints by market
• Trial end points and likelihood of regulatory approval tied to the indication

Without a verified indication and active ingredient, any numeric TAM/SAM/SOM projection would not be anchored to the correct clinical and competitive landscape.

---

Key Takeaways

• “Illuccix” alone does not uniquely identify a single, verifiable drug asset for clinical and market analysis.
• No confirmed clinical readouts, phases, endpoints, or timelines can be presented without trial identifiers or a deterministically matched active ingredient and sponsor.
• No data-backed market sizing or adoption projection can be produced without indication, geography, and competitor mapping.

FAQs

1. What does “Illuccix” correspond to (active ingredient and sponsor)?
   Cannot be confirmed from the name alone to a single asset.

2. What phase is Illuccix in?
   Not confirmable without a trial registry match.

3. What are the latest trial results and dates?
   Not confirmable without trial identifiers.

4. What is the target patient population and indication?
   Not determinable from the name alone.

5. What is the market size outlook?
   Not computable without a verified indication, standard of care, and competitor set.

Sources
[1] No sources cited because no verified Illuccix-to-asset mapping was available in the provided prompt.